

Special Issue

Advances in the Field of Biofilm-Associated Musculoskeletal Infections

Message from the Guest Editor

The Special Issue aims to cover a range of novel advances (original research and reviews) on the following topics: 1) Anti-biofilm active agents in biofilm-associated musculoskeletal infections;

2) Are fracture-related infections biofilm-associated infections?

3) The relation between MBEC and MIC when treating biofilm-associated musculoskeletal infections;

4) Mycobacterial-associated musculoskeletal infections and implant-related infections: what is new?

5) Are biofilm-associated musculoskeletal infections different between high-income countries and low-income countries?

6) Updates on phage therapy in biofilm-associated musculoskeletal infections.

Guest Editor

Dr. Kordo Saeed

1. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK

2. Department of Microbiology, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK

Deadline for manuscript submissions

10 October 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/217654

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)